{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:01:53Z","timestamp":1789614113831,"version":"build-2803163510"},"reference-count":236,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Radiotherapy (RT) is evolving from local cytotoxicity to systemic immunomodulation. Acting as an\n                      <jats:italic>in situ<\/jats:italic>\n                      vaccine, RT initiates antitumor immunity via immunogenic cell death and cGAS-STING activation. However, RT concurrently triggers counter-regulatory immunosuppression\u2014upregulating PD-L1\/TGF-\u03b2, expanding Tregs\/MDSCs, and inducing T-cell exhaustion\u2014limiting durable systemic control.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrate preclinical mechanisms and key clinical evidence for radioimmunotherapy combinations. We analyze how radiation dose, fractionation, and delivery techniques remodel the tumor immune microenvironment and outline matching therapeutic strategies<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Optimal combination requires balancing local tumor control with systemic immune activation while preserving lymphoid reserves. Consolidation durvalumab following concurrent chemoradiotherapy has been shown to improve survival in patients with unresectable stage III non-small cell lung cancer, and SBRT combined with PD-(L)1 blockade has demonstrated benefits in oligometastatic settings. Conversely, radioimmunotherapy combinations have yielded disappointing outcomes in extensive-stage small cell lung cancer and head and neck cancers. Low-dose RT and novel spatial-fractionation strategies offer emerging solutions to reverse immune exclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Efficacy hinges on converting RT-induced immunoadaptation into productive antitumor immunity. Future progress demands biomarker-driven patient selection (e.g., tumor mutational burden, chromosomal instability) and precise orchestration of multi-modality timing. Transitioning toward \u201cimmunologically guided precision radiotherapy\u201d will transform RT from a static local therapy into a dynamic component of systemic cancer care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2026.1927654","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:05:36Z","timestamp":1789610736000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond local control: radiotherapy\u2013immunotherapy combinations from in situ vaccination to systemic immune remodeling"],"prefix":"10.3389","volume":"17","author":[{"given":"Yulong","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Nantong University School of Medicine","place":["Nantong, China"]},{"name":"Department of Radiotherapy, Nantong Tumor Hospital","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Nantong University School of Medicine","place":["Nantong, China"]},{"name":"Department of Radiotherapy, Nantong Tumor Hospital","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Nantong University School of Medicine","place":["Nantong, China"]},{"name":"Department of Radiotherapy, Nantong Tumor Hospital","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Nantong University School of Medicine","place":["Nantong, China"]},{"name":"Department of Radiotherapy, Nantong Tumor Hospital","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Nantong University School of Medicine","place":["Nantong, China"]},{"name":"Department of Radiotherapy, Nantong Tumor Hospital","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/s1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1158\/0008-5472.Can-20-2870","article-title":"GLUT1 expression in tumor-associated neutrophils promotes lung cancer growth and resistance to radiotherapy","volume":"81","author":"Ancey","year":"2021","journal-title":"Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hemonc.2021.11.001","article-title":"Radiotherapy and immunotherapy in Melanoma brain metastases","volume":"16","author":"Anvari","year":"2023","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","article-title":"Tumor-reprogrammed resident T cells resist radiation to control tumors","volume":"10","author":"Arina","year":"2019","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/jco.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s43018-021-00245-1","article-title":"Radiation-activated secretory proteins of Scgb1a1(+) club cells increase the efficacy of immune checkpoint blockade in lung cancer","volume":"2","author":"Ban","year":"2021","journal-title":"Nat. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e000537","DOI":"10.1136\/jitc-2020-000537","article-title":"Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma","volume":"8","author":"Barsoumian","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/cancers14010221","article-title":"High plus low dose radiation strategy in combination with TIGIT and PD1 blockade to promote systemic antitumor responses","volume":"14","author":"Barsoumian","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth Factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1073\/pnas.0902745106","article-title":"IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation","volume":"106","author":"Ben-Sasson","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.20122006","article-title":"IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells","volume":"210","author":"Ben-Sasson","year":"2013","journal-title":"J. Exp. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8845","DOI":"10.1038\/s41467-024-53015-9","article-title":"Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade","volume":"15","author":"Bergeron","year":"2024","journal-title":"Nat. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.4049\/jimmunol.2000194","article-title":"Dendritic cell maturation defines immunological responsiveness of tumors to radiation therapy","volume":"204","author":"Blair","year":"2020","journal-title":"J. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)","volume":"34","author":"Brunelli","year":"2009","journal-title":"Eur. Respir. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40425-017-0305-7","article-title":"Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial","volume":"5","author":"Canter","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1046028","DOI":"10.1080\/2162402x.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.semcancer.2022.04.003","article-title":"Radiation therapy-induced remodeling of the tumor immune microenvironment","volume":"86","author":"Charpentier","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"371819","DOI":"10.1155\/2013\/371819","article-title":"Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study","volume":"2013","author":"Chen","year":"2013","journal-title":"Biomed Res. Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00066-014-0708-z","article-title":"Radiation-induced VEGF-C expression and endothelial cell proliferation in lung cancer","volume":"190","author":"Chen","year":"2014","journal-title":"Strahlenther Onkol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e000492","DOI":"10.1136\/jitc-2019-000492","article-title":"Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials","volume":"8","author":"Chen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00262-020-02690-w","article-title":"Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"eabc7609","DOI":"10.1126\/sciadv.abc7609","article-title":"Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy","volume":"7","author":"Cheng","year":"2021","journal-title":"Sci. Adv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1125905","DOI":"10.3389\/fimmu.2023.1125905","article-title":"Mechanistic rationales for combining immunotherapy with radiotherapy","volume":"14","author":"Chi","year":"2023","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"110235","DOI":"10.1016\/j.radonc.2024.110235","article-title":"Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: an interim analysis of the EORTC-ESTRO E(2)-RADIatE OligoCare study","volume":"195","author":"Christ","year":"2024","journal-title":"Radiother. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"86522","DOI":"10.18632\/oncotarget.13287","article-title":"Increasing the efficacy of radiotherapy by modulating the CCR2\/CCR5 chemokine axes","volume":"7","author":"Connolly","year":"2016","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"B36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41577-021-00568-1","article-title":"Immunomodulation by radiotherapy in tumour control and normal tissue toxicity","volume":"22","author":"Cytlak","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/jco.21.02528","article-title":"Management of stage III non-small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/jci67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"","journal-title":"J. Clin. Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/cco.0000000000000006","article-title":"Current status of interleukin-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.Ccr-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2326-6066.Cir-17-0581","article-title":"Exosomes shuttle TREX1-Sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs","volume":"6","author":"Diamond","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","article-title":"Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity","volume":"502","author":"Donlon","year":"2021","journal-title":"Cancer Lett."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.Can-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.Ccr-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/cncr.33083","article-title":"A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179","volume":"126","author":"Durm","year":"2020","journal-title":"Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e002242","DOI":"10.1136\/jitc-2020-002242","article-title":"Neutrophils in the era of immune checkpoint blockade","volume":"9","author":"Faget","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.radonc.2010.02.007","article-title":"Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes","volume":"95","author":"Fernandes","year":"2010","journal-title":"Radiother. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGFbeta","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","article-title":"Radiation therapy to convert the tumor into an in situ vaccine","volume":"84","author":"Formenti","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/2159-8290.Cd-18-0743","article-title":"In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/jco.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.Cd-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.Cir-13-0115","article-title":"An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer","volume":"1","author":"Golden","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","article-title":"Combined radiotherapy and Anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer","volume":"12","author":"Gong","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/jci73639","article-title":"PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J. Clin. Invest"},{"key":"B69","doi-asserted-by":"publisher","first-page":"108553","DOI":"10.1016\/j.lungcan.2025.108553","article-title":"Multimodality treatment in synchronous oligometastatic NSCLC: analysis of the ETOP CHESS trial","volume":"204","author":"Guckenberger","year":"2025","journal-title":"Lung Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41467-020-15404-8","article-title":"TGF\u03b2 suppresses CD8(+) T cell expression of CXCR3 and tumor trafficking","volume":"11","author":"Gunderson","year":"2020","journal-title":"Nat. Commun."},{"key":"B71","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1073\/pnas.1812186116","article-title":"Differential control of human treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody","volume":"116","author":"Ha","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B73","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ejca.2021.08.029","article-title":"PI3K\u03b3\u03b4 inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model","volume":"157","author":"Han","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/cancers14112692","article-title":"Combination of OX40 co-stimulation, radiotherapy, and PD-1 inhibition in a syngeneic murine triple-negative breast cancer model","volume":"14","author":"Han","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"215928","DOI":"10.1016\/j.canlet.2022.215928","article-title":"Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a Murine tumor model","volume":"550","author":"Hartmann","year":"2022","journal-title":"Cancer Lett."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","article-title":"Radiotherapy to enhance chimeric antigen receptor T-Cell therapeutic efficacy in solid tumors: a narrative review","volume":"7","author":"Hauth","year":"2021","journal-title":"JAMA Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1158\/2326-6066.Cir-22-0547","article-title":"Inhibition of STAT6 with antisense oligonucleotides enhances the systemic antitumor effects of radiotherapy and Anti-PD-1 in metastatic non-small cell lung cancer","volume":"11","author":"He","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: a double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"key":"B79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3322\/caac.21358","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"B80","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.it.2022.01.006","article-title":"Lighting up the tumor fire with low-dose irradiation","volume":"43","author":"Herrera","year":"","journal-title":"Trends Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.Cd-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"","journal-title":"Cancer Discov."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e87415","DOI":"10.1172\/jci.insight.87415","article-title":"Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer","volume":"1","author":"Herter-Sprie","year":"2016","journal-title":"JCI Insight"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11060-004-4204-7","article-title":"Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines-a clue to radioresistance?","volume":"74","author":"Hovinga","year":"2005","journal-title":"J. Neurooncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.4049\/jimmunol.1402898","article-title":"IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1","volume":"195","author":"Hsu","year":"2015","journal-title":"J. Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1002\/cncr.33197","article-title":"Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma","volume":"126","author":"Hu","year":"2020","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3389\/fonc.2020.01610","article-title":"The impacts of different types of radiation on the CRT and PDL1 expression in tumor cells under normoxia and hypoxia","volume":"10","author":"Huang","year":"2020","journal-title":"Front. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s43018-025-01018-w","article-title":"Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer","volume":"6","author":"Huang","year":"","journal-title":"Nat. Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.32604\/or.2025.066805","article-title":"Igniting cold tumors: multi-Omics-driven strategies to overcome immune evasion and restore immune surveillance","volume":"33","author":"Huang","year":"","journal-title":"Oncol. Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrclinonc.2012.194","article-title":"Image-guided radiotherapy: from current concept to future perspectives","volume":"9","author":"Jaffray","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e005103","DOI":"10.1136\/jitc-2022-005103","article-title":"Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization","volume":"10","author":"Jagodinsky","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/2326-6066.Cir-21-1105","article-title":"Myeloid-derived suppressor cells and radiotherapy","volume":"10","author":"Jim\u00e9nez-Cortegana","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B96","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/1078-0432.Ccr-16-0870","article-title":"Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma","volume":"23","author":"Kalbasi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.trecan.2019.10.013","article-title":"Unmasking the many faces of tumor-associated neutrophils and macrophages: considerations for targeting innate immune cells in cancer","volume":"5","author":"Keeley","year":"2019","journal-title":"Trends Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure)","volume":"27","author":"Kim","year":"2016","journal-title":"Ann. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/emm.2006.56","article-title":"Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1078-0432.Ccr-15-1535","article-title":"Combination therapy with Anti-PD-1, Anti-TIM-3, and focal radiation results in regression of murine gliomas","volume":"23","author":"Kim","year":"","journal-title":"Clin. Cancer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"41242","DOI":"10.18632\/oncotarget.17168","article-title":"Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model","volume":"8","author":"Kim","year":"","journal-title":"Oncotarget"},{"key":"B103","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1172\/jci40283","article-title":"Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice","volume":"120","author":"Kioi","year":"2010","journal-title":"J. Clin. Invest"},{"key":"B104","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/annonc\/mdx790","article-title":"Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: building better translational research platforms","volume":"29","author":"Kordbacheh","year":"2018","journal-title":"Ann. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.trecan.2022.06.002","article-title":"Vascular damage in tumors: a key player in stereotactic radiation therapy?","volume":"8","author":"Kozin","year":"2022","journal-title":"Trends Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1158\/0008-5472.Can-09-4446","article-title":"Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation","volume":"70","author":"Kozin","year":"2010","journal-title":"Cancer Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/s1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/s1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2017","journal-title":"Lancet Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3389\/fimmu.2019.02857","article-title":"Local irradiation sensitized tumors to adoptive T cell therapy via enhancing the cross-priming, homing, and cytotoxicity of antigen-specific CD8 T cells","volume":"10","author":"Lai","year":"2019","journal-title":"Front. Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijrobp.2018.01.071","article-title":"Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy","volume":"101","author":"Lan","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ccell.2021.08.008","article-title":"Simultaneous targeting of TGF-\u03b2\/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion","volume":"39","author":"Lan","year":"2021","journal-title":"Cancer Cell"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2158013","DOI":"10.1080\/2162402x.2022.2158013","article-title":"Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors","volume":"12","author":"Laurent","year":"2023","journal-title":"Oncoimmunology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2432726","DOI":"10.1080\/2162402x.2024.2432726","article-title":"Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7(th) immunorad conference","volume":"14","author":"Laurent","year":"2025","journal-title":"Oncoimmunology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e29259","DOI":"10.4161\/onci.29259","article-title":"STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression","volume":"3","author":"Le Bert","year":"2014","journal-title":"Oncoimmunology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"e138740","DOI":"10.1172\/jci138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J. Clin. Invest"},{"key":"B119","doi-asserted-by":"publisher","first-page":"113952","DOI":"10.1016\/j.intimp.2024.113952","article-title":"Unleashing the power of immune checkpoints: a new strategy for enhancing treg cells depletion to boost antitumor immunity","volume":"147","author":"Li","year":"","journal-title":"Int. Immunopharmacol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1097\/cm9.0000000000003609","article-title":"Immunotherapy and radiotherapy: an effective combination in cancer treatment","volume":"138","author":"Li","year":"","journal-title":"Chin. Med. J. Engl."},{"key":"B121","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/ijc.25087","article-title":"Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It's no longer the question: a systematic review","volume":"127","author":"Liang","year":"2010","journal-title":"Int. J. Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"Liang","year":"2017","journal-title":"Nat. Commun."},{"key":"B123","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ijrobp.2020.07.2326","article-title":"Potentiating antitumor efficacy through radiation and sustained intratumoral delivery of Anti-CD40 and Anti-PDL1","volume":"110","author":"Liu","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B124","doi-asserted-by":"publisher","first-page":"53474","DOI":"10.1021\/acsami.4c09825","article-title":"STING agonist delivered by neutrophil membrane-coated gold nanoparticles exerts synergistic tumor inhibition with radiotherapy","volume":"16","author":"Lu","year":"2024","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B125","doi-asserted-by":"publisher","first-page":"9080","DOI":"10.4081\/hr.2021.9080","article-title":"Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed\/refractory classical Hodgkin lymphoma: a retrospective analysis in 12 patients","volume":"13","author":"Lucchini","year":"2021","journal-title":"Hematol. Rep."},{"key":"B126","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J. Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/jco.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"e2102611118","DOI":"10.1073\/pnas.2102611118","article-title":"Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads","volume":"118","author":"Lussier","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B129","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00262-022-03325-y","article-title":"Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites","volume":"72","author":"Martin","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"B131","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/imr.13427","article-title":"Fc effector function of immune checkpoint blocking antibodies in oncology","volume":"328","author":"Martineau","year":"2024","journal-title":"Immunol. Rev."},{"key":"B132","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ygyno.2017.02.009","article-title":"The significance of tumor-associated neutrophil density in uterine cervical cancer treated with definitive radiotherapy","volume":"145","author":"Matsumoto","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1667\/rr1860.1","article-title":"Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation","volume":"173","author":"Matsumura","year":"2010","journal-title":"Radiat. Res."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J. Immunol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cllc.2021.01.012","article-title":"A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer","volume":"22","author":"Mattes","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"B136","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/jco.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B138","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/2326-6066.Cir-18-0633","article-title":"CCR2-Dependent recruitment of tregs and monocytes following radiotherapy is associated with TNF\u03b1-Mediated resistance","volume":"7","author":"Mondini","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"e1395996","DOI":"10.1080\/2162402x.2017.1395996","article-title":"PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation","volume":"7","author":"Morisada","year":"2018","journal-title":"Oncoimmunology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science"},{"key":"B143","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/2326-6066.Cir-17-0040","article-title":"Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ccell.2015.03.015","article-title":"Radiotherapy complements immune checkpoint blockade","volume":"27","author":"Ngiow","year":"2015","journal-title":"Cancer Cell"},{"key":"B146","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s43018-022-00456-0","article-title":"Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect","volume":"3","author":"Nishiga","year":"2022","journal-title":"Nat. Cancer"},{"key":"B148","doi-asserted-by":"publisher","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","article-title":"Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies","volume":"9","author":"Nishikawa","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e001764","DOI":"10.1136\/jitc-2020-001764","article-title":"Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy","volume":"9","author":"Olivo Pimentel","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/jnci\/djz036","article-title":"STAT3 modulation of regulatory T cells in response to radiation therapy in head and neck cancer","volume":"111","author":"Oweida","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat. Immunol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.Cir-14-0138","article-title":"PD-1 restrains radiotherapy-induced abscopal effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B153","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","article-title":"Pan-asian adapted ESMO clinical practice guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS","volume":"31","author":"Park","year":"2020","journal-title":"Ann. Oncol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.radonc.2021.06.037","article-title":"High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial","volume":"162","author":"Patel","year":"2021","journal-title":"Radiother. Oncol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e004306","DOI":"10.1136\/jitc-2021-004306","article-title":"Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade","volume":"10","author":"Patin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B156","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.Cd-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"B157","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijrobp.2020.09.031","article-title":"Prospective single-arm phase 1 and 2 study: Ipilimumab and nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer","volume":"109","author":"Perez","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B158","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","article-title":"Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European thoracic oncology platform NICOLAS phase II trial (European thoracic oncology platform 6-14)","volume":"16","author":"Peters","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"e002715","DOI":"10.1136\/jitc-2021-002715","article-title":"Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice","volume":"9","author":"Pieper","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1830524","DOI":"10.1080\/2162402x.2020.1830524","article-title":"Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade","volume":"9","author":"Pilones","year":"2020","journal-title":"Oncoimmunology"},{"key":"B161","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/jco.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1200\/jco.22.00204","article-title":"Durvalumab induces sustained survival benefit after concurrent chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Pujol","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijrobp.2019.10.047","article-title":"A pilot study of atezolizumab plus hypofractionated image guided radiation therapy for the treatment of advanced non-small cell lung cancer","volume":"108","author":"Qin","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B167","doi-asserted-by":"publisher","first-page":"813832","DOI":"10.3389\/fimmu.2021.813832","article-title":"CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors","volume":"12","author":"Qin","year":"2021","journal-title":"Front. Immunol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"B169","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Trends Immunol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e1442166","DOI":"10.1080\/2162402x.2018.1442166","article-title":"Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients","volume":"7","author":"Roger","year":"2018","journal-title":"Oncoimmunology"},{"key":"B171","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive cellular therapies: the current landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab before and after chemoradiation for unresectable stage III non-small cell lung cancer: a phase II nonrandomized controlled trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol. Rev."},{"key":"B174","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/2326-6066.Cir-17-0134","article-title":"Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells","volume":"6","author":"Rudqvist","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1771925","DOI":"10.1080\/2162402x.2020.1771925","article-title":"A liposomal RNA vaccine inducing neoantigen-specific CD4(+) T cells augments the antitumor activity of local radiotherapy in mice","volume":"9","author":"Salomon","year":"2020","journal-title":"Oncoimmunology"},{"key":"B176","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat. Immunol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1158\/1078-0432.Ccr-07-4462","article-title":"T-cell responses to survivin in cancer patients undergoing radiation therapy","volume":"14","author":"Schaue","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B179","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.Cir-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-Mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B180","doi-asserted-by":"publisher","first-page":"e000340","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B181","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ijrobp.2021.05.014","article-title":"Regulatory T cells shape the differential impact of radiation dose-fractionation schedules on host innate and adaptive antitumor immune defenses","volume":"111","author":"Sia","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/s43018-022-00467-x","article-title":"Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade","volume":"3","author":"Spurr","year":"2022","journal-title":"Nat. Cancer"},{"key":"B184","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/neuonc\/nov272","article-title":"Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization","volume":"18","author":"Stafford","year":"2016","journal-title":"Neuro Oncol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.3390\/ijms21228877","article-title":"The impact of radiation-induced DNA damage on cGAS-STING-Mediated immune responses to cancer","volume":"21","author":"Storozynsky","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B186","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/lymphatics1030018","article-title":"Incorporating immunotherapy with radiotherapy for lymphomas","volume":"1","author":"Strati","year":"2023","journal-title":"Lymphatics"},{"key":"B187","doi-asserted-by":"publisher","first-page":"15440","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat. Commun."},{"key":"B188","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41419-023-05829-6","article-title":"Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia","volume":"14","author":"Sugita","year":"2023","journal-title":"Cell Death Dis."},{"key":"B189","doi-asserted-by":"publisher","first-page":"766200","DOI":"10.3389\/fimmu.2022.766200","article-title":"Combination of Anti-PD-1 antibody, anlotinib and pegaspargase \u201csandwich\u201d with radiotherapy in localized natural Killer\/T cell lymphoma","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ijrobp.2017.11.029","article-title":"Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma","volume":"100","author":"Sundahl","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.4049\/jimmunol.1000488","article-title":"Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer","volume":"185","author":"Tabi","year":"2010","journal-title":"J. Immunol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"2507856","DOI":"10.1080\/2162402x.2025.2507856","article-title":"Updates on radiotherapy-immunotherapy combinations: proceedings of 8th annual ImmunoRad conference","volume":"14","author":"Talebi","year":"2025","journal-title":"Oncoimmunology"},{"key":"B193","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1078-0432.Ccr-16-1432","article-title":"Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells","volume":"23","author":"Tang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B195","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrclinonc.2012.203","article-title":"Past, present, and future of radiotherapy for the benefit of patients","volume":"10","author":"Thariat","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s2213-2600(20)30391-x","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B198","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/srep17016","article-title":"Kill-painting of hypoxic tumours in charged particle therapy","volume":"5","author":"Tinganelli","year":"2015","journal-title":"Sci. Rep."},{"key":"B199","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"B200","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ijrobp.2022.06.090","article-title":"Microbeam radiation therapy controls local growth of radioresistant melanoma and treats out-of-field locoregional metastasis","volume":"114","author":"Trappetti","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B201","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ijrobp.2007.01.041","article-title":"Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth","volume":"68","author":"Tsai","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B202","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"B203","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B204","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/0008-5472.Can-14-3511","article-title":"TGF\u03b2 is a master regulator of radiation therapy-induced antitumor immunity","volume":"75","author":"Vanpouille-Box","year":"2015","journal-title":"Cancer Res."},{"key":"B205","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"B206","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2018.05.013","article-title":"Cytosolic DNA sensing in organismal tumor control","volume":"34","author":"Vanpouille-Box","year":"2018","journal-title":"Cancer Cell"},{"key":"B207","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cllc.2022.06.005","article-title":"A review of concurrent chemo\/radiation, immunotherapy, radiation planning, and biomarkers for locally advanced non-small cell lung cancer and their role in the development of ECOG-ACRIN EA5181","volume":"23","author":"Varlotto","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"B208","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semradonc.2014.07.008","article-title":"Myeloid-derived cells in tumors: effects of radiation","volume":"25","author":"Vatner","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/0008-5472.Can-12-0210","article-title":"Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies","volume":"72","author":"Verbrugge","year":"2012","journal-title":"Cancer Res."},{"key":"B211","doi-asserted-by":"publisher","first-page":"eabh4050","DOI":"10.1126\/sciadv.abh4050","article-title":"Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8","volume":"8","author":"Walle","year":"2022","journal-title":"Sci. Adv."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.medj.2024.06.002","article-title":"Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer","volume":"5","author":"Wang","year":"","journal-title":"Med"},{"key":"B213","doi-asserted-by":"publisher","first-page":"e20232101","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"","journal-title":"J. Exp. Med."},{"key":"B214","doi-asserted-by":"publisher","first-page":"20240145","DOI":"10.1002\/VIW.20240145","article-title":"Circulating genomic biomarkers predict chemoradiotherapy resistance and immunotherapy response in locally advanced non-small-cell lung cancer","volume":"6","author":"Wang","year":"2025","journal-title":"VIEW"},{"key":"B215","doi-asserted-by":"publisher","first-page":"e001100","DOI":"10.1136\/jitc-2020-001100","article-title":"Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer","volume":"8","author":"Ware","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B216","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"e001001","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jtho.2020.08.022","article-title":"Phase 1\/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC","volume":"15","author":"Welsh","year":"","journal-title":"J. Thorac. Oncol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1158\/2326-6066.Cir-19-0449","article-title":"CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection","volume":"8","author":"Wennerberg","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"B220","doi-asserted-by":"publisher","first-page":"E484","DOI":"10.1073\/pnas.1323253111","article-title":"RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation","volume":"111","author":"Widau","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B221","doi-asserted-by":"publisher","first-page":"18584","DOI":"10.1073\/pnas.1901562116","article-title":"Neutrophils promote tumor resistance to radiation therapy","volume":"116","author":"Wisdom","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B222","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/jco.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-Dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B224","doi-asserted-by":"publisher","first-page":"e1477459","DOI":"10.1080\/2162402x.2018.1477459","article-title":"Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment","volume":"7","author":"Wu","year":"2018","journal-title":"Oncoimmunology"},{"key":"B225","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/0008-5472.Can-12-3981","article-title":"CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res."},{"key":"B226","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/cancers14092087","article-title":"High dose local photon irradiation is crucial in Anti-CTLA-4 antibody therapy to enhance the abscopal response in a murine pancreatic carcinoma model","volume":"14","author":"Yamamoto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B227","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13014-015-0482-9","article-title":"Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study","volume":"10","author":"Yamashita","year":"2015","journal-title":"Radiat. Oncol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","article-title":"Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and Anti-PD1 in mice and patients with non-small cell lung cancer","volume":"108","author":"Yin","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B229","doi-asserted-by":"publisher","first-page":"989190","DOI":"10.3389\/fonc.2022.989190","article-title":"Dynamic alterations in PD-1\/PD-L1 expression level and immune cell profiles based on radiation response status in mouse tumor model","volume":"12","author":"Yoon","year":"2022","journal-title":"Front. Oncol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/01.coc.0000256691.27796.24","article-title":"A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer","volume":"30","author":"Yuan","year":"2007","journal-title":"Am. J. Clin. Oncol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/j.jtho.2017.04.029","article-title":"Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1-Negative metastatic squamous cell carcinoma of the lung","volume":"12","author":"Yuan","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijrobp.2018.01.094","article-title":"Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-Cell response","volume":"101","author":"Zhang","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B233","doi-asserted-by":"publisher","first-page":"e2010333118","DOI":"10.1073\/pnas.2010333118","article-title":"ICAM-1 orchestrates the abscopal effect of tumor radiotherapy","volume":"118","author":"Zhao","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/cam4.1344","article-title":"Validating the pivotal role of the immune system in low-dose radiation-induced tumor inhibition in lewis lung cancer-bearing mice","volume":"7","author":"Zhou","year":"2018","journal-title":"Cancer Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/s1470-2045(21)00630-6","article-title":"Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"key":"B236","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/jmrs.540","article-title":"A scoping review of patient selection methods for proton therapy","volume":"69","author":"Zientara","year":"2022","journal-title":"J. Med. Radiat. Sci."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1927654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:05:39Z","timestamp":1789610739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1927654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":236,"alternative-id":["10.3389\/fgene.2026.1927654"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1927654","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1927654"}}